2024 Common Rule Report on Executive Branch’s “deceptive implicature” Depriving Service Members & Healthcare Providers

Want Instant Blog Updates?

Get an email whenever we publish a new article!
PLEASE NOTE:
This subscribe option does not work in some browsers with ad blockers. To ensure your sign up request goes through, use the Google Chrome browser when confirming your subscription from your inbox.

March 19, 2024

Brain Ward is a personal hero of mine and is meeting with Congress in DC in reference to the 2024 Common Rule Report this week.

Brian Ward is “gifted in solving complex problems and was approached in the fall of 2021 by members of the Armed Forces and in the fall of 2022 by healthcare workers to solve the COVID-19 vaccine mandate problem. This document represents 2,000 hours dedicated to fulfilling his promise to service members and healthcare workers to restore their equality before the law and to secure what was stolen from them, including the dignity of the healthcare worker and the honor of the military profession. A PDF copy of this report can be downloaded at COVIDPenalty.com”.

This report details the “Executive Branch’s use of “deceptive implicature” to deprive DOD service members, CMS healthcare providers, and green card workers of rights created for their benefit by valid acts of Congress to refuse investigational new drugs without consequence”.

Example of Report Contents

DECEPTIVE IMPLICATURE & COMMON RULE

The FDA approved COMIRNATY® on August 23, 2021, but Pfizer never manufactured its original or “tris-sucrose” licensed versions to introduce them into commerce for general commercial marketing. Starting on August 24, 2021, the Executive branch, DoD, CMS, state governors, hospitals, and other authorities set into motion a series of communications designed to mislead the American people into the false belief that all of Pfizer’s COVID-19 drugs were effectively FDA licensed with a legal indication to prevent the coronavirus since it “shared formulation” with a licensed drug.


Access the full report here

We've got a lot to talk about

Read More